A new report from NHS Digital shows that a decreasing number of children are being vaccinated against potentially deadly or life-altering diseases such as tetanus, diphtheria and polio
News
Almirall steps into psoriasis market with Ilumetri approval
The European Commission has approved Almirall’s Ilumetri for moderate-to-severe chronic plaque psoriasis.
Actelion’s Opsumit shows promise in portopulmonary hypertension
Actelion has unveiled new data showing that the first ever randomised, controlled clinical trial investigating Opsumit as potential treatment for portopulmonary hypertension (PoPH) hit its primary target.
Allergan, Sosei suspend clinical development of dementia drug
Allergan and Sosei are voluntarily suspending clinical development activities with HTL0018318 pending investigation of an unexpected toxicology finding in an animal study involving non-human primates.
AZ’ Fasenra shows long-term efficacy in eosinophilic asthma
AstraZeneca has unveiled data from a Phase III extension trial highlighting the efficacy of biologic Fasenra as an add-on maintenance treatment in patients with severe eosinophilic asthma.
CR UK invests £14m in London cancer biotherapeutics hub
Cancer Research UK is investing some £14 million into transforming the city of London into a “world-leading hub for cancer biotherapeutics”.
New study to explore genetic links to depression and anxiety
Researchers are calling for 40,000 people with depression or anxiety in England to join an online study hoping to explore any genetic links to these conditions.
Allergan snaps up Bonti
Irish pharma Allergan is buying privately-held, clinical-stage US biotech Bonti for access to its novel, fast-acting neurotoxin programmes for aesthetic and therapeutic applications.
NICE nod for Novartis’ targeted skin cancer combo
The National Institute for Health and Care Excellence has backed NHS funding for Novartis’ oral targeted adjuvant combination therapy Tafinlar and Mekinist, offering new hope to patients with a specific type of skin cancer.
Teva’s anti-CGRP drug Ajovy cleared for migraine prevention
US regulators have approved Teva’s Ajovy for the preventative treatment of migraine in adults.
AZ to file triple combination therapy for COPD
AstraZeneca has unveiled late-stage data backing use of its triple combination therapy PT010 in patients with chronic obstructive pulmonary disease (COPD).
It’s an industry affair – New Medical & Scientific Excellence Awards attracting entrants by the day
Medical Science Liaison of the Year has been expanded to include three levels of seniority and forms the backbone of the all new Medical and Scientific Excellence Awards, alongside categories for scientific advisors and medical information professionals.
ViiV submits two-drug regimen for HIV in Europe
ViiV Healthcare has submitted an application in Europe for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.
NHS summer performance hits new lows
Alarm bells over the NHS’ ability to cope with looming winter pressures are ringing again after some aspects of service performance sunk to new lows in the summer, with record waiting times for A&E and cancer treatment.
Landmark MS trial launches in UK
The biggest ever trial for secondary progressive multiple sclerosis (SPMS) has kicked off in the UK at around 30 sites in England, Scotland, Wales, Northern Ireland and Eire.
